BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

500 related articles for article (PubMed ID: 30427812)

  • 1. Is Ketamine the Future Clozapine for Depression? A Case Series and Literature Review on Maintenance Ketamine in Treatment-resistant Depression With Suicidal Behavior.
    Chan LF; Eu CL; Soh SY; Maniam T; Shahidii Kadir Z; Chong BTW; Loo JL; Sharip S; Wong VCW; Loo TH; Ng YP; Kahn DA
    J Psychiatr Pract; 2018 Jul; 24(4):279-291. PubMed ID: 30427812
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rapid and longer-term antidepressant effects of repeated-dose intravenous ketamine for patients with unipolar and bipolar depression.
    Zheng W; Zhou YL; Liu WJ; Wang CY; Zhan YN; Li HQ; Chen LJ; Li MD; Ning YP
    J Psychiatr Res; 2018 Nov; 106():61-68. PubMed ID: 30278319
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A review of ketamine in affective disorders: current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action.
    Naughton M; Clarke G; O'Leary OF; Cryan JF; Dinan TG
    J Affect Disord; 2014 Mar; 156():24-35. PubMed ID: 24388038
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Repeat-dose ketamine augmentation for treatment-resistant depression with chronic suicidal ideation: A randomized, double blind, placebo controlled trial.
    Ionescu DF; Bentley KH; Eikermann M; Taylor N; Akeju O; Swee MB; Pavone KJ; Petrie SR; Dording C; Mischoulon D; Alpert JE; Brown EN; Baer L; Nock MK; Fava M; Cusin C
    J Affect Disord; 2019 Jan; 243():516-524. PubMed ID: 30286416
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of a Rapid Intravenous Injection of Ketamine 0.5 mg/kg in Treatment-Resistant Major Depression: An Open 4-Week Longitudinal Study.
    Vidal S; Gex-Fabry M; Bancila V; Michalopoulos G; Warrot D; Jermann F; Dayer A; Sterpenich V; Schwartz S; Vutskits L; Khan N; Aubry JM; Kosel M
    J Clin Psychopharmacol; 2018 Dec; 38(6):590-597. PubMed ID: 30346333
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Maintenance of antidepressant and antisuicidal effects by D-cycloserine among patients with treatment-resistant depression who responded to low-dose ketamine infusion: a double-blind randomized placebo-control study.
    Chen MH; Cheng CM; Gueorguieva R; Lin WC; Li CT; Hong CJ; Tu PC; Bai YM; Tsai SJ; Krystal JH; Su TP
    Neuropsychopharmacology; 2019 Nov; 44(12):2112-2118. PubMed ID: 31421635
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neurocognitive effects of six ketamine infusions and the association with antidepressant response in patients with unipolar and bipolar depression.
    Zhou Y; Zheng W; Liu W; Wang C; Zhan Y; Li H; Chen L; Li M; Ning Y
    J Psychopharmacol; 2018 Oct; 32(10):1118-1126. PubMed ID: 30260273
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antisuicidal effect, BDNF Val66Met polymorphism, and low-dose ketamine infusion: Reanalysis of adjunctive ketamine study of Taiwanese patients with treatment-resistant depression (AKSTP-TRD).
    Chen MH; Lin WC; Wu HJ; Cheng CM; Li CT; Hong CJ; Tu PC; Bai YM; Tsai SJ; Su TP
    J Affect Disord; 2019 May; 251():162-169. PubMed ID: 30925267
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Subanesthetic ketamine infusions for suicide ideation in patients with bipolar and unipolar treatment refractory depression.
    Kang MJY; Kulcar E; Chandrasena R; Anjum MR; Fairbairn J; Hawken ER; Vazquez GH
    Psychiatry Res; 2021 Feb; 296():113645. PubMed ID: 33360430
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Continuation phase intravenous ketamine in adults with treatment-resistant depression.
    Vande Voort JL; Morgan RJ; Kung S; Rasmussen KG; Rico J; Palmer BA; Schak KM; Tye SJ; Ritter MJ; Frye MA; Bobo WV
    J Affect Disord; 2016 Dec; 206():300-304. PubMed ID: 27656788
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ketamine for the treatment of depression.
    Howland RH
    J Psychosoc Nurs Ment Health Serv; 2013 Jan; 51(1):11-4. PubMed ID: 23413455
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Randomized, Double-Blind, Midazolam-Controlled Trial of Low-Dose Ketamine Infusion in Patients With Treatment-Resistant Depression and Prominent Suicidal Ideation.
    Su TP; Li CT; Lin WC; Wu HJ; Tsai SJ; Bai YM; Mao WC; Tu PC; Chen LF; Li WC; Chen MH
    Int J Neuropsychopharmacol; 2023 May; 26(5):331-339. PubMed ID: 36966411
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Randomized, Double-Blind, Placebo-Controlled Pilot Trial of the Acute Antisuicidal and Antidepressant Effects of Intranasal (R,S)-Ketamine in Severe Unipolar and Bipolar Depression With and Without Comorbid Alcohol Use Disorder.
    Jones GH; Vecera CM; Ruiz AC; Wu HE; McInturff SI; Orejarena MJ; Smith KA; Soares JC; Zarate CA; Lane SD; Machado-Vieira R
    J Clin Psychiatry; 2024 Apr; 85(2):. PubMed ID: 38696221
    [No Abstract]   [Full Text] [Related]  

  • 14. Rapid and Sustained Reductions in Current Suicidal Ideation Following Repeated Doses of Intravenous Ketamine: Secondary Analysis of an Open-Label Study.
    Ionescu DF; Swee MB; Pavone KJ; Taylor N; Akeju O; Baer L; Nyer M; Cassano P; Mischoulon D; Alpert JE; Brown EN; Nock MK; Fava M; Cusin C
    J Clin Psychiatry; 2016 Jun; 77(6):e719-25. PubMed ID: 27232360
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rapid and sustained antidepressant effects of intravenous ketamine in treatment-resistant major depressive disorder and suicidal ideation: a randomized clinical trial.
    Zolghadriha A; Anjomshoaa A; Jamshidi MR; Taherkhani F
    BMC Psychiatry; 2024 May; 24(1):341. PubMed ID: 38714931
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effectiveness of repeated intravenous ketamine on depressive symptoms, suicidal ideation and functional disability in adults with major depressive disorder and bipolar disorder: Results from the Canadian Rapid Treatment Center of Excellence.
    McIntyre RS; Rodrigues NB; Lee Y; Lipsitz O; Subramaniapillai M; Gill H; Nasri F; Majeed A; Lui LMW; Senyk O; Phan L; Carvalho IP; Siegel A; Mansur RB; Brietzke E; Kratiuk K; Arekapudi AK; Abrishami A; Chau EH; Szpejda W; Rosenblat JD
    J Affect Disord; 2020 Sep; 274():903-910. PubMed ID: 32664031
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ketamine-induced affective switch in a patient with treatment-resistant depression.
    Banwari G; Desai P; Patidar P
    Indian J Pharmacol; 2015; 47(4):454-5. PubMed ID: 26288483
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A preliminary study of anti-suicidal efficacy of repeated ketamine infusions in depression with suicidal ideation.
    Zhan Y; Zhang B; Zhou Y; Zheng W; Liu W; Wang C; Li H; Chen L; Yu L; Walter M; Li M; Li MD; Ning Y
    J Affect Disord; 2019 May; 251():205-212. PubMed ID: 30927581
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors of Response to Ketamine in Treatment Resistant Major Depressive Disorder and Bipolar Disorder.
    Rong C; Park C; Rosenblat JD; Subramaniapillai M; Zuckerman H; Fus D; Lee YL; Pan Z; Brietzke E; Mansur RB; Cha DS; Lui LMW; McIntyre RS
    Int J Environ Res Public Health; 2018 Apr; 15(4):. PubMed ID: 29673146
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single, Repeated, and Maintenance Ketamine Infusions for Treatment-Resistant Depression: A Randomized Controlled Trial.
    Phillips JL; Norris S; Talbot J; Birmingham M; Hatchard T; Ortiz A; Owoeye O; Batten LA; Blier P
    Am J Psychiatry; 2019 May; 176(5):401-409. PubMed ID: 30922101
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.